Navigation Links
Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
Date:8/28/2009

approval."

Outline of the EXAMINE Trial

    Title:             A Multicenter, Randomized, Double-Blind, Placebo-
                       Controlled Study to Evaluate Cardiovascular Outcomes
                       Following Treatment with Alogliptin in Addition to
                       Standard of Care in Subjects with Type 2 Diabetes and
                       Acute Coronary Syndrome

    Study Start:       September 2009

    Study Completion:  December 2014

    No. of Patients:   Approximately 5,400

    Primary Outcome:   Time from randomization to the occurrence of the
                       Primary Major Adverse Cardiac Events defined as
                       a composite of cardiovascular death, nonfatal
                       myocardial infarction and nonfatal stroke

    Secondary Outcome: Time from randomization to the occurrence of the
                       Secondary Major Adverse Cardiac Events defined
                       as a composite of cardiovascular death, nonfatal
                       myocardial infarction, nonfatal stroke and urgent
                       revascularization due to unstable angina

    Study Sites:       Approximately 1,000 sites in the U.S., Europe, Asia

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate Web site, www.takeda.com.

About Takeda Pharmaceuticals North America, Inc. and Takeda Globa
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
11. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Intelomed is pleased to announce that ... as the Vice President of Clinical Affairs. With over ... device industry, Kay,s experience in taking medical technology and ... to global expansion, is a valuable addition to the ... on our team, and I am confident her focused ...
(Date:8/26/2014)... Research and Markets has announced ... Report 2014 " report to their offering. ... is a professional and in-depth study on the current ... The report provides a basic overview of the industry ... glucose meter market analysis is provided for both the ...
(Date:8/26/2014)... DUBLIN , Aug. 26, 2014 ... "Global Intranasal Drug Delivery Market 2014-2018" report ... is a medical device used for the administration of ... nose and paranasal sinus such as allergic and non-allergic ... an ideal administrative route for needle-free vaccination and systematic ...
Breaking Medicine Technology:Mary Kay Deck joins Intelomed as Vice President of Clinical Affairs 2Global Glucose Meter Industry Report 2014 2Global Glucose Meter Industry Report 2014 3Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3
(Date:8/27/2014)... 2014 Aspirus Wausau Hospital today announced ... with Buzz™ Digital O.R. at Aspirus Wausau Hospital, in ... new operating rooms will be Buzz, a centralized surgical ... system supports planning, navigation, imaging and communications connectivity. ... intuitive software and hardware all controlled from the full ...
(Date:8/27/2014)... 26, 2014 (HealthDay News) -- Health care workers in ... to keep them safe from being infected with blood-borne ... shows. While the study was conducted before the ... its findings are confirmed in statistics released Monday by ... agency reported that an "unprecedented" number of health care ...
(Date:8/27/2014)... patients are 70 per cent more likely to continue ... they have a prescription in hand when discharged ... the Institute for Clinical Evaluative Sciences (ICES). , Using ... Ontarians were taking their medications one week, one year ... reveal the importance of simple interventions, such as giving ...
(Date:8/27/2014)... Hills, CA (PRWEB) August 27, 2014 Bedros ... camp franchise in the world, the leading fitness boot ... Spike TV’s Gym Rescue reality series. One thing he knows ... brand as a subject matter expert in the fitness business. ... to YouTube, he lays out a step-by-step instructional guide on ...
(Date:8/27/2014)... Phoenix, AZ (PRWEB) August 27, 2014 ... that serves the greater Phoenix metropolitan area and all ... client more than $160,000 on a $2 million settlement. ... tangible savings to those who have been injured through ... can be complex and time-consuming, however Hastings and Hastings ...
Breaking Medicine News(10 mins):Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 2Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 3Health News:A prescription for better stroke care 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $166,700 On A Settlement Of $2,000,000 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $166,700 On A Settlement Of $2,000,000 3
... has been released by Australian obesity experts that show gastric ... conference on obesity in Sydney there were three studies which ... in mortality rates in obese people who had the surgery. ... upper part of the stomach for the procedure to restrict ...
... a 4- to 5-point IQ advantage over women by adulthood. ... to 18-year-//olds on the Scholastic Assessment Test (SAT). ... because girls mature faster than boys. This is the reason ... ,145 items from the SAT were examined by a study ...
... of the opinion that eating nuts about twice a week might ... that was presented at the World Congress of Cardiology stated that ... would be around a small plate full might reduce the risk ... survey confirmed that eating a small quantity of the same kinds ...
... hang heavy with heart problems, going back at least two ... she hit age 50,// Catherine got nervous. ,A ... and perhaps those of others in her family tree. She ... causes her heart muscle to grow too thick. The extra ...
... Industry in China has placed on record the successful initial ... vaccine is said to operate in low doses, nearly one-third ... undertaken till date. The smaller doses are proven to be ... observed that just two 10-microgram doses of the Sinovac vaccine, ...
... Scottish Executive have announced their plans to offer dental students ... them in the NHS.// ,It has been explained ... given ?4,000 a year in return for a commitment of ... ,Lewis Macdonald, the deputy health minister, had announced the launch ...
Cached Medicine News:Health News:Greater g factor in men responsible for sex differences in general mental ability 2Health News:Greater g factor in men responsible for sex differences in general mental ability 3Health News:Fight Back Against Inherited Sudden-Death Heart Condition 2Health News:Fight Back Against Inherited Sudden-Death Heart Condition 3Health News:Fight Back Against Inherited Sudden-Death Heart Condition 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: